Surgery Partners, Inc. (SGRY)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-11-05
$23.17+0.04%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-11-05
QuarterlyIQ Insights · SGRY
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-11-05.
The screen ranks SGRY against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
2026 Outlook The Company reaffirmed its outlook for 2026 revenues to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million, excluding the impact of the recent…
Stated in 2 of 2 supplied quarters. Management reported: “2026 Outlook The Company reaffirmed its outlook for 2026 revenues to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million, excluding the impact of the recently disclosed pending divestiture of our facilities in Idaho Falls, Idaho.” “1 2026 Outlook The Company reaffirmed its outlook for 2026 revenues to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million.”
“2026 Outlook The Company reaffirmed its outlook for 2026 revenues to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million, excluding the impact of the recent…”
“1 2026 Outlook The Company reaffirmed its outlook for 2026 revenues to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million.”
The announcement of the pending Idaho Falls transaction was a key achievement and represents an important step forward in our portfolio optimization strategy, as we take decisive actions to improve o…
Stated in 2 of 2 supplied quarters. Management reported: “The announcement of the pending Idaho Falls transaction was a key achievement and represents an important step forward in our portfolio optimization strategy, as we take decisive actions to improve our financial profile and sharpen our strategic focus.” “Our portfolio optimization efforts also remain critical to our long-term strategy as we take steps to better align with our core short-stay surgical operating model.”
The Idaho Falls transaction, which remains subject to closing conditions including physician members and governing board approvals, will further strengthen our financial position, through improved ca…
Stated in 2 of 2 supplied quarters. Management reported: “The Idaho Falls transaction, which remains subject to closing conditions including physician members and governing board approvals, will further strengthen our financial position, through improved cash conversion and deleveraging.” “Through disciplined execution, and a continued focus on improving free cash flow and reducing leverage, we are well-positioned to return the business to consistent growth, while delivering on long-term shareholder value.””
Looking ahead, we will capitalize on the structural tailwinds underpinning long-term ASC market growth, enhance operational efficiency, and thoughtfully deploy capital to deliver long-term value for…
Stated in 2 of 2 supplied quarters. Management reported: “Looking ahead, we will capitalize on the structural tailwinds underpinning long-term ASC market growth, enhance operational efficiency, and thoughtfully deploy capital to deliver long-term value for our shareholders.”” “As we continue to navigate near-term market dynamics, our cost management discipline and continued execution on physician recruitment position us well to meet or exceed our 2026 plan.”
Use portfolio actions to better align operations with the core short-stay surgical model and improve the financial profile.
Over the trailing year it converted -1.39x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
12 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.
“The announcement of the pending Idaho Falls transaction was a key achievement and represents an important step forward in our portfolio optimization strategy, as we take decisive actions to improve o…”
“Our portfolio optimization efforts also remain critical to our long-term strategy as we take steps to better align with our core short-stay surgical operating model.”
“The Idaho Falls transaction, which remains subject to closing conditions including physician members and governing board approvals, will further strengthen our financial position, through improved ca…”
“Through disciplined execution, and a continued focus on improving free cash flow and reducing leverage, we are well-positioned to return the business to consistent growth, while delivering on long-te…”
“Looking ahead, we will capitalize on the structural tailwinds underpinning long-term ASC market growth, enhance operational efficiency, and thoughtfully deploy capital to deliver long-term value for…”
“As we continue to navigate near-term market dynamics, our cost management discipline and continued execution on physician recruitment position us well to meet or exceed our 2026 plan.”